ABOUT INSEPTION GROUP
inSeption Group is a global full-service outsourcing organization built upon a foundational culture of exceptional service and quality.
This culture attracts a subset of industry experts who value your assets as much as you do and take personal responsibility for delivering on what has been promised. Our ability to integrate these dedicated professionals into your teams results in unmatched execution and continuity.
inSeption Group offers full-service outsourcing, functional service provider solutions, and consulting services specializing in oncology, hematology, neurodegenerative disorders, rare disease, and cell and gene therapy.
VIDEOS
-
Discover essential strategies to prevent clinical trials from reaching a crisis while gaining a deeper understanding of the importance of addressing systemic issues early.
-
Explore some of the major challenges that medical writing submission specialists face today and strategies that can consistently set the stage for success.
-
Delve into the significance of adept interpersonal leadership within your drug safety program, shedding light on the operational and financial benefits that stem from fostering a collaborative environment.
-
In part two of this webinar series, presenters focus on avoiding potential risks, such as unexpected budget changes and unplanned change orders, that could jeopardize the success of a clinical trial.
-
Watch this presentation to equip stakeholders with actionable strategies and a comprehensive understanding of the evolving clinical trial management landscape in the context of ICH guidelines.
-
Gain insight from several clinical operations experts into the significance of meticulous contract examination when choosing an outsourcing partner.
-
Everything we do is driven to challenge the status quo in the current outsourcing paradigm. inSeption is a home for clients and professionals who have been stifled by mainstream, high-volume, commoditized outsourcing models.
CONTACT INFORMATION
inSeption Group
870 W Main Street
Lansdale, PA 19446
UNITED STATES
Phone: (267) 498-5092
FEATURED ARTICLES
- Diverse Mentorship Models Create Multiple Paths To Employee Success
- The Critical Role Of The Medical Monitor
- Strategies For A More Secure Outsourcing Bottom Line
- How To Establish Effective, Scalable Drug Safety Ops Across Vendors
- How To Unlock The Secret To Repeatable, Scalable Low Turnover
- Treating Deficiencies In Employee Training And Mentorship
- Shifting The Approach: 4 Tactics For ICH E6(R3) Implementation
- The Write Side Of AI: Augmenting Capabilities, Not Replacing Them
- Modernize TMF Culture To Better Support Modern Clinical Trials
- How Sponsors And Patients Benefit From A Site-Centric Partnership
- Uncovering Hidden CRO Contract Costs Before Signing A Contract
- Accelerated Development: Gene Therapy Vs. Small Molecule
- Outsourcing Vendor Red Flag #3: Inaccurate Or Low Bids
- Outsourcing Vendor Red Flag #2: Oversight And Process
- Outsourcing Vendor Red Flags: Bids And Contracts
- The Power And Potential Of RBM In Clinical Trials
- Remote Work Success Is Built On Pre-Site And Site Initiation Visits
- Rare Disease Clinical Endpoints: Ingenuity Meets Practicality
- Gene Therapy Natural History Studies: Benefits, Timing, And Execution
- Regulatory Submission Crisis Rescue: When To Take Action
MYTHBUSTERS
-
09/20/21 Life Science Leader Newsletter
-
Large CROs have a vast pool of resources and a subset of amazingly talented people. However, the decision to select such a CRO on the concept that they have access to the best talent, and the hope that those resources will be assigned to your study, is flawed.
-
Most quantitative and qualitative studies seeking to understand what creates fear and anxiety in humans conclude with some version of the same 4 key criteria: Lack of Control, Large Consequence, Sudden Occurrence, and Unfamiliarity. In our outsourcing industry, it is never an easy decision to select a partner when trying to run complex sequential trials. The need to gain regulatory approval for the treatments you have dedicated yourself to providing, coupled with the need to find a capable, reliable, and fair Contract Research Organization is quite daunting.
-
The theory of Corporate Memory is easy to understand and agree with – the better you record and understand recurring actions the better you will perform those actions. Read why Capitalizing on corporate memory might work at an individual level but is nothing more than a myth and an empty promise in the complex changing world of drug clinical studies.
-
Have you ever asked yourself why you take comfort with governance agreements? They're created to "protect" you when your CRO fails - and even then, what can you realistically do? Find out the answers here.
E-BOOKS
-
Gene therapy has existed for decades, but the field is not as mature as it may seem. Here, the author provides essential insights and strategies for overcoming gene therapy development challenges.
-
Delve into four articles regarding dissecting the critical resources, processes, and key stakeholders essential for the successful completion of an ACT clinical trial.
-
Discover how biopharmaceutical sponsors in clinical trials leverage real-time data analytics and conduct comprehensive gap analyses to improve trial efficiency and overcome study challenges, such as patient recruitment and retention, risk mitigation, and evolving patient expectations.
-
Discover how clinical research services must wade through a bog of incomplete information, and sometimes outright misinformation, when it comes to seeking reliable partnerships.
-
Biopharma companies — particularly smaller or emerging organizations — often are unable to draw maximum value from CROs. This occurs for any number of reasons, several of which are covered in this e-book.